These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24359616)

  • 21. Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells.
    Xu X; He Y; Miao X; Wu Y; Han J; Wang Q; Liu J; Zhong F; Ou Y; Wang Y; He S
    Leuk Res; 2016 Aug; 47():54-62. PubMed ID: 27258734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Regulatory Axis, CHD1L-MicroRNA 486-Matrix Metalloproteinase 2, Controls Spermatogonial Stem Cell Properties.
    Liu SS; Maguire EM; Bai YS; Huang L; Liu Y; Xu L; Fauzi I; Zhang SQ; Xiao Q; Ma NF
    Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transgenic CHD1L expression in mouse induces spontaneous tumors.
    Chen M; Huang JD; Hu L; Zheng BJ; Chen L; Tsang SL; Guan XY
    PLoS One; 2009 Aug; 4(8):e6727. PubMed ID: 19701453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma.
    Liu ZH; Zhang Q; Ding YJ; Ren YH; Yang HP; Xi Q; Cheng YN; Miao GL; Liu HK; Li CX; Yan WQ; Li Y; Xue Z; Zhang L; Li XY; Zhao CL; Da Y; Wu XZ; Chen JQ; Zhang R; Li ZG
    Oncotarget; 2017 Sep; 8(43):74178-74187. PubMed ID: 29088777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The validation of new CHD1L inhibitors as a therapeutic strategy for cancer.
    Clune S; Awolade P; Zhou Q; Esquer H; Matter B; Kearns JT; Kellett T; Akintayo DC; Kompella UB; LaBarbera DV
    Biomed Pharmacother; 2024 Jan; 170():116037. PubMed ID: 38128184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
    Abbott JM; Zhou Q; Esquer H; Pike L; Broneske TP; Rinaldetti S; Abraham AD; Ramirez DA; Lunghofer PJ; Pitts TM; Regan DP; Tan AC; Gustafson DL; Messersmith WA; LaBarbera DV
    Mol Cancer Ther; 2020 Aug; 19(8):1598-1612. PubMed ID: 32499299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors.
    Liu M; Chen L; Ma NF; Chow RK; Li Y; Song Y; Chan TH; Fang S; Yang X; Xi S; Jiang L; Li Y; Zeng TT; Li Y; Yuan YF; Guan XY
    Hepatology; 2016 May; 63(5):1544-59. PubMed ID: 27100146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHD1L Promotes Neuronal Differentiation in Human Embryonic Stem Cells by Upregulating PAX6.
    Dou D; Zhao H; Li Z; Xu L; Xiong X; Wu X; Sun Y; Zeng S; Ouyang Q; Zhou D; Ma N; Lin G; Hu L
    Stem Cells Dev; 2017 Nov; 26(22):1626-1636. PubMed ID: 28946814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer.
    Wang W; Wu J; Fei X; Chen W; Li Y; Shen K; Zhu L
    Am J Transl Res; 2019; 11(3):1581-1592. PubMed ID: 30972184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L.
    Prigaro BJ; Esquer H; Zhou Q; Pike LA; Awolade P; Lai XH; Abraham AD; Abbott JM; Matter B; Kompella UB; Messersmith WA; Gustafson DL; LaBarbera DV
    J Med Chem; 2022 Mar; 65(5):3943-3961. PubMed ID: 35192363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CHD1L: a new candidate gene for congenital anomalies of the kidneys and urinary tract (CAKUT).
    Brockschmidt A; Chung B; Weber S; Fischer DC; Kolatsi-Joannou M; Christ L; Heimbach A; Shtiza D; Klaus G; Simonetti GD; Konrad M; Winyard P; Haffner D; Schaefer F; Weber RG
    Nephrol Dial Transplant; 2012 Jun; 27(6):2355-64. PubMed ID: 22146311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
    Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
    Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromodomain-helicase-DNA-binding protein 1-like (CHD1L) silencing inhibits gastric cancer cell proliferation, invasion, and migration.
    Li D; Li C; Wang Y; Wang Y; Li Q; Wang L
    Transl Cancer Res; 2020 Nov; 9(11):6660-6671. PubMed ID: 35117276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks.
    Blessing C; Mandemaker IK; Gonzalez-Leal C; Preisser J; Schomburg A; Ladurner AG
    Mol Cell; 2020 Dec; 80(5):862-875.e6. PubMed ID: 33275888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Poly-ADP-Ribose Trigger Releases the Auto-Inhibition of a Chromatin Remodeling Oncogene.
    Singh HR; Nardozza AP; Möller IR; Knobloch G; Kistemaker HAV; Hassler M; Harrer N; Blessing C; Eustermann S; Kotthoff C; Huet S; Mueller-Planitz F; Filippov DV; Timinszky G; Rand KD; Ladurner AG
    Mol Cell; 2017 Dec; 68(5):860-871.e7. PubMed ID: 29220653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pan-cancer analysis reveals CHD1L as a prognostic and immunological biomarker in several human cancers.
    Soltan MA; Eldeen MA; Eid RA; Alyamani NM; Alqahtani LS; Albogami S; Jafri I; Park MN; Alsharif G; Fayad E; Mohamed G; Osman R; Kim B; Zaki MSA
    Front Mol Biosci; 2023; 10():1017148. PubMed ID: 37033447
    [No Abstract]   [Full Text] [Related]  

  • 37. Chromatin remodeler ALC1 prevents replication-fork collapse by slowing fork progression.
    Ooka M; Abe T; Cho K; Koike K; Takeda S; Hirota K
    PLoS One; 2018; 13(2):e0192421. PubMed ID: 29408941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diversity roles of CHD1L in normal cell function and tumorigenesis.
    Xiong X; Lai X; Li A; Liu Z; Ma N
    Biomark Res; 2021 Mar; 9(1):16. PubMed ID: 33663617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromodomain helicase/ATPase DNA binding protein 1-like protein expression predicts poor prognosis in nasopharyngeal carcinoma.
    Su FR; Ding JH; Bo L; Liu XG
    Exp Ther Med; 2014 Dec; 8(6):1745-1750. PubMed ID: 25371726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CHD1L is a novel independent prognostic factor for gastric cancer.
    Su Z; Zhao J; Xian G; Geng W; Rong Z; Wu Y; Qin C
    Clin Transl Oncol; 2014 Aug; 16(8):702-7. PubMed ID: 24258459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.